Affimed N.V. reports developments as a clinical-stage immuno-oncology company focused on innate cell engager, or ICE, molecules generated from its proprietary ROCK platform. Company news centers on AFM24 in non-small cell lung cancer, including monotherapy and combinations with atezolizumab, and acimtamig in combination with AlloNK, as well as scientific meeting presentations and clinical data updates.
Affimed’s recent corporate updates also cover its filing for the opening of insolvency proceedings in Germany and Nasdaq listing matters, including deficiency notices, trading suspension, and delisting of its common shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.